Compounds Useful Against Acute Neurogenic Inflammation
- Technology Benefits
- The bis-heterocyclic compounds represent a basis for the development of novel therapeutics for the control of neurogenic pain and inflammation.
- Technology Application
- The bis-heterocyclic compounds may be useful in the treatment of: Chronic pain, migraines, and arthritis. Inflammatory conditions that involve a neurogenic pain-producing component, such as certain metastic carcinomas or inflammation of the blood vessels. Skin conditions, including radiation irritation and burns, chemical burns, rhinitis, thermal burns, and reddening of the skin. Allergic responses.
- Detailed Technology Description
- Researchers at the University of California have discovered that bis-heterocyclic compounds are highly effective in inhibiting neurogenic inflammation. The compounds, pharmaceutical preparations including the compounds, and methods for administering the compounds are available.
- Supplementary Information
- Patent Number: US5955462A
Application Number: US1997961475A
Inventor: Jacobs, Robert S. | Pomponi, Shirley A. | Gunasekera, Sarath P. | Wright, Amy E.
Priority Date: 31 Oct 1996
Priority Number: US5955462A
Application Date: 31 Oct 1997
Publication Date: 21 Sep 1999
IPC Current: C07D040314 | A61K003100 | A61K00314025 | A61K00314045 | A61K00314178 | A61K0031496 | A61K0031497 | A61P001702 | A61P002500 | A61P002900 | A61P003708 | C07D020914
US Class: 51425409 | 514254 | 51425505 | 514397 | 514402 | 514497
Assignee Applicant: Harbor Branch Oceanographic Institution Inc.,Fort Pierce | The Regents of the Univ. of California,Oakland
Title: Anti-neurogenic inflammatory compounds and compositions and methods of use thereof
Usefulness: Anti-neurogenic inflammatory compounds and compositions and methods of use thereof
Summary: USE The method is for treating pain particularly caused by migraine, rhinitis and thermal-, radiation- and chemical- induced pain, chemical-, radiation- and thermal- burns and allergic response and for promoting wound healing. The dosage of (I) is 0.01-20 mg/kg intravenously, by aerosol or by intranasal instillation, 0.01-100 mg/kg intraperitoneally, subcutaneously or intramuscularly or 0.01-200 (preferably 1-100) mg/kg.
Novelty: Inhibiting or controlling neurogenic inflammation using bis-heterocyclic compound, used for treating chemical, radiation and thermal burns and allergic response
- Industry
- Chemical/Material
- Sub Category
- Chemical/Material Application
- Application No.
- 5955462
- Others
-
Tech ID/UC Case
10092/1997-118-0
Related Cases
1997-118-0
- *Abstract
-
Inflammation is a significant clinical issue, the prevention and control of which is of prime importance. There are two main types of inflammation, called cellular inflammation and neurogenic inflammation. Cellular inflammation is mediated by activation of specific immune cells, whereas neurogenic inflammation is mediated directly by activation of nociceptive and thermal-sensitive endings in tissues.
Much research has been devoted to the development of compounds having anti-inflammatory properties, particularly from marine animals. For example, topsentins, nortopsentins, dragmacidin, homocarbonyltopsentins, and hamacathins are a group of compounds, called bis-heterocyclic compounds, derived from sea sponges that have been shown to have inhibitory activity against cellular inflammatory responses.
- *IP Issue Date
- Sep 21, 1999
- *Principal Investigator
-
Name: Sarath P. Gunasekera
Department:
Name: Robert Jacobs
Department:
Name: Shirley A. Pomponi
Department:
Name: Amy Wright
Department:
- Country/Region
- USA
